07:43 AM EDT, 09/16/2025 (MT Newswires) -- Eli Lilly's ( LLY ) investigational oral weight-loss drug orforglipron could be approved by the US Food and Drug Administration before the end of the year under a new one-to-two-month priority review process, Reuters reported Tuesday, citing Wall Street analysts.

Analysts see the drug as a strong candidate for the fast-track program, which aims to speed approvals for medicines that cut costs or address major health concerns, according to the report.

Goldman Sachs ( GS ) estimates an earlier launch of the drug by one quarter would bring in another $1 billion in revenue to Lilly, the report said.

Eli Lilly ( LLY ) and the US FDA did not immediately respond to MT Newswires' request for comment.

(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)